DIA
Drug Information Association Logo

FROM BIOMARKERS TO COMPANION DIAGNOSTICS

Track:
Personalised Medicine: Drug-companion diagnostics combinations

Day & Time:
March 26, 11:00AM - 12:30PM (Central European Standard Time)

Session Number:
0502

Room Number:
Room I

Type:
Session

Title:
FROM BIOMARKERS TO COMPANION DIAGNOSTICS

Chair(s):
Jens Grueger, PhD
Head Global Pricing & Market Access, Pharma Division
F. Hoffmann-La Roche, Switzerland

Description:
This session will cover validation and regulation of drug-diagnostics combinations, introduction of personalised medicine innovations in clinical practice, corporate and governmental pharmaceutical and diagnostic coordination, and introduction of personalised medicine in to clinical practice.

Presentation(s) & Speaker(s):
Current Regulation and Challenges for Biomarker and Companion IVD Development – focus on biotech products
Joerg Engelbergs, PhD
Scientific-regulatory expert for antibody based therapeutics and biomarkers
Paul-Ehrlich-Institut, Germany

Developments in Companion Diagnostics/PHC
Rainer Metzger
Qiagen, Germany

Introduction Therapy/Test Combination in Clinical Practice
Robert Mader
Director of Translational Research,
Dept. of Medicine I, Comprehensive Cancer Centre Medical University of Vienna, Austria